Latest News

LED sign that reads CAR T Cells
HOPA News Late Breaking News

Late-Breaking HOPA News: CAR-T Approval Updates

CAR-T approval updates show the treatment moving up the rung in Multiple Myeloma and breaking ground in Chronic Lymphocytic Leukemia

Medical illustration of male kidneys and bladder
HOPA News Late Breaking News

Late-Breaking HOPA News: EV-302 and CheckMate 901 Trials and Other Genitourinary Studies

In October of 2023, several practice-changing presentations about genitourinary cancers were made during the annual European Society for Medical Oncology (ESMO) Congress.

HOPA News Late Breaking News

Late-Breaking HOPA News: COMMANDS Study for Myelodysplastic Syndrome

The COMMANDS study was a phase 3, open-label, multicenter, randomized controlled trial. Patients were eligible for enrollment if they were 18 years or older, diagnosed with very low risk, low risk or intermediate risk MDS, ESA-naïve, and requiring red blo

HOPA News

3 FEATURE Indication Withdrawals of Small Molecule Inhibitors from the Accelerated Approval Program

The United States Food and Drug Administration’s (FDA) Accelerated Approval Program, which expedites approval of drugs and biologics that treat serious conditions such as cancer, has drawn criticism for allowing products to reach the market only to see th

colonoscopy image
HOPA News Late Breaking News

Late-Breaking HOPA News: Colorectal Cancer Screening Updates & Review of NordICC

The Nordic-European Initiative on Colorectal Cancer (NordICC) trial is the first randomized controlled trial (RCT) to evaluate efficacy of CRC screening on risk of CRC development and related death.

HOPA News

National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey

Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. The purpose of this survey was to characterize the